Panitumumab & Low-Dose Capecitabine: Promising Maintenance Therapy for Metastatic Colorectal Cancer
May 7, 2025
Discover groundbreaking research on a new maintenance therapy for metastatic colorectal cancer that combines panitumumab and low-dose capecitabine. This innovative approach aims to extend survival and improve quality of life without the severe side effects of conventional treatments. Learn how this gentler option can make cancer care more accessible for patients around the world, transforming the way doctors manage the challenges of advanced cancer.
06:48
forum Ask episode
web_stories AI Snips
view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
insights INSIGHT
mCRC Treatment Challenges
Metastatic colorectal cancer (mCRC) is harder to treat and one of the leading causes of cancer death worldwide.
Current strong chemotherapy regimens are effective but cause severe side effects limiting long-term use.
insights INSIGHT
Standard Therapy Side Effects
Standard mCRC treatments like FOLFOX and CAPOX include strong drugs causing serious side effects.
Oxaliplatin leads to nerve damage; fatigue and diarrhea are common, often limiting therapy continuation.
insights INSIGHT
Role of Maintenance Therapy
Maintenance therapy uses gentler treatments after initial cancer control to prevent relapse.
Finding therapies with sustained effectiveness but fewer side effects is crucial, especially in resource-limited settings.
Get the Snipd Podcast app to discover more snips from this episode
A recent #study from Assiut University Hospital in Egypt, published in #Oncotarget, presents a promising strategy for patients with metastatic #colorectalcancer (mCRC). The #research introduces a gentler yet effective maintenance therapy that may extend survival, enhance quality of life, and offer a more accessible treatment option for mCRC patients worldwide.
The Challenge of Treating Metastatic Colorectal Cancer
Colorectal cancer is one of the most common causes of cancer-related deaths worldwide. When it spreads to other parts of the body—a stage known as mCRC—it becomes much more difficult to treat. At this stage, clinicians often use strong drug combinations like FOLFOX or CAPOX, which mix chemotherapy drugs to stop cancer growth. FOLFOX combines three drugs given intravenously, while CAPOX includes two of the same drugs, with one taken as a pill.
While effective, these treatments can cause serious side effects. For example, one of the main drugs, oxaliplatin, can lead to nerve damage, making it painful or difficult to use the hands and feet. Fatigue, diarrhea, and other issues are also common. Over time, these side effects may force clinicians to stop or adjust the treatment, even if it is working.
That is where maintenance therapy comes in. After the cancer is controlled, clinicians often switch to a gentler treatment plan to keep it from returning. The challenge is finding a therapy that continues to work without causing too many side effects, especially in places where access to expensive or intensive treatments is limited.
Full blog - https://www.oncotarget.org/2025/05/07/panitumumab-and-low-dose-capecitabine-a-promising-maintenance-therapy-for-metastatic-colorectal-cancer/
Paper DOI - https://doi.org/10.18632/oncotarget.28687
Correspondence to - Doaa A. Gamal - doaaalygamaal@gmail.com
Video short - https://www.youtube.com/watch?v=wuPSS0EdK-8
Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28687
Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/
Keywords - cancer, Panitumumab, maintenance, colorectal cancer, Capecitabine
About Oncotarget
Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.
Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science).
To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:
Facebook - https://www.facebook.com/Oncotarget/
X - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/@OncotargetJournal
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/
Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh
MEDIA@IMPACTJOURNALS.COM
Oncotarget